A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone

The purpose of this study was to observe and evaluate the tolerability, safety, and pharmacokinetics of HRS-1167 combined with abiraterone acetate tablets (II) and prednisone in patients with metastatic prostate cancer, determine the RP2D, and evaluate the effectiveness.

Trial Details

NCT ID
NCT06689163
Phase
PHASE1 / PHASE2
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • HRS-1167 tablets
  • Abiraterone Acetate tablets(II)
  • Prednisone Acetate tablets
Locations (sample)
  • Hefei, Anhui, China|31.86389,117.28083
  • Changsha, Hunan, China|28.19874,112.97087

Key Eligibility Criteria

  • Voluntary participation in this study, signed informed consent, compliance is good, and are willing and able to comply with planned visits.
  • The age is above 18 years old, male.
  • Adenocarcinoma of the prostate confirmed with histologically or cytologically.
  • Metastatic lesions were confirmed by CT/MRI or radionuclide bone scan (99mTc).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →